Genentech to pay up to $350 million for Bayhill's diabetes candidate
This article was originally published in Scrip
Executive Summary
Genentech is to pay the US private biopharmaceutical company Bayhill Therapeutics $25 million up-front and potential milestones of more than $325 million to develop and commercialise BHT-3021, a DNA-based antigen specific immunotherapy in Phase I/II clinical trials in patients with type 1 diabetes.